Real-time enrollment status for this metastatic castration resistant prostate cancer (mcrpc) clinical trial
Current Status
Recruiting
Checked: October 12, 2026 at 1:45 PM UTC
| NCT Number | NCT03460977 |
| Recruiting Status | Recruiting |
| Condition | Metastatic Castration Resistant Prostate Cancer (mCRPC) |
| Phase | PHASE1 |
| Target Enrollment | 453 participants |
| Active Locations | 45 sites in the US |
| Sponsor | Pfizer |
| Last Updated on CT.gov | October 2, 2026 (1 week ago) |
As of October 12, 2026: Clinical trial NCT03460977 is currently recruiting participants. This phase1 study for metastatic castration resistant prostate cancer (mcrpc) is actively seeking new participants at 45 locations across the United States. The study is sponsored by Pfizer. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT03460977 is actively recruiting participants as of October 12, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 45 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT03460977 was last updated 1 week ago (October 2, 2026). HelloStudys verifies this status automatically.